Evaluating the Efficacy and Safety of Transitioning Patients from Natalizumab to Ocrelizumab (OCTAVE)

Authors

Kyle E Smoot, Providence Multiple Sclerosis Center, Providence Brain & Spine Institute, Portland, OregonFollow
Kiren Kresa-Reahl, Providence Multiple Sclerosis Center, Providence Brain & Spine Institute, Portland, OregonFollow
Pavle Repovic, Multiple Sclerosis Center, Swedish Neuroscience Institute, Seattle, WashingtonFollow
Jessica Craddock, Providence Multiple Sclerosis Center, Providence Sacred Heart Medical Center, Spokane, WashingtonFollow
Chiayi Chen, Providence Multiple Sclerosis Center, Providence Sacred Heart Medical Center, Spokane, WashingtonFollow
Lindsay Lucas, Providence Multiple Sclerosis Center, Providence Sacred Heart Medical Center, Spokane, Washington
Tiffany Gervasi-Follmar, Providence Multiple Sclerosis Center, Providence Sacred Heart Medical Center, Spokane, WashingtonFollow
Stanley Cohan, Providence Multiple Sclerosis Center, Providence Sacred Heart Medical Center, Spokane, WashingtonFollow

Files

Publication Date

5-2019

Disciplines

Neurology

Clinical Institute

Neurosciences (Brain & Spine)

Specialty/Research Institute

Neurosciences

Conference / Event Name

American Academy of Neurology Annual Meeting

Location

Philadelphia, PA, United States